Atypical antipsychotics and hyperglycemic emergencies: Multicentre, retrospective cohort study of administrative data

Schizophrenia Research

Volumn 154, Issue 1-3, 2014, Pages 54-60

  Lipscombe, Lorraine L ^a,l   Austin, Peter C ^a   Alessi Severini, Silvia ^b,c   Blackburn, David F ^d   Blais, Lucie ^e   Bresee, Lauren ^f   Filion, Kristian B ^g,h   Kawasumi, Yuko ⁱ   Kurdyak, Paul ^a,m   Platt, Robert W ^g   Tamim, Hala ^j,k   Paterson, J Michael ^a  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f ALBERTA HEALTH SERVICES   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j DALHOUSIE UNIVERSITY   (Canada)

^k YORK UNIVERSITY   (Canada)

^l WOMEN S COLLEGE HOSPITAL   (Canada)

^m CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

more..

Author keywords

Antipsychotics; Database research; Diabetes; Drug side effects; Epidemiology; Hyperglycemic emergencies; Psychosis

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG SAFETY; EMERGENCY CARE; FEMALE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UNITED KINGDOM; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES COMPLICATIONS; META ANALYSIS (TOPIC); MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RISK; SCHIZOPHRENIA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84897020225     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.01.043     Document Type: Article

References (37)

1. Allison D.B., Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J. Clin. Psychiatry 2001, 62(Suppl. 7):22-31.
2. Austin P.C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res. 2011, 46(3):399-424.
3. Bobo W.V., Cooper W.O., Epstein R.A., Arbogast P.G., Mounsey J., Ray W.A. Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a Tennessee medicaid study. BMC Med. Res. Methodol. 2011, 11:157.
4. Buse J.B., Cavazzoni P., Hornbuckle K., Hutchins D., Breier A., Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J. Clin. Epidemiol. 2003, 56(2):164-170.
5. Caro J.J., Ward A., Levinton C., Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J. Clin. Psychiatry 2002, 63(12):1135-1139.
6. Citrome L., Jaffe A., Levine J., Allingham B., Robinson J. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr. Serv. 2004, 55(9):1006-1013.
7. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 2000, 26(4):903-912.
8. DuMouchel W., Fram D., Yang X., Mahmoud R.A., Grogg A.L., Engelhart L., Ramaswamy K. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Ann. Clin. Psychiatry 2008, 20(1):21-31.
9. Gianfrancesco F., Grogg A., Mahmoud R., Wang R.H., Meletiche D. Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin. Ther. 2003, 25(4):1150-1171.
10. Gianfrancesco F., White R., Wang R.H., Nasrallah H.A. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J. Clin. Psychopharmacol. 2003, 23(4):328-335.
11. Gianfrancesco F., Pesa J., Wang R.H., Nasrallah H. Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design. Am. J. Health Syst. Pharm. 2006, 63(5):431-441.
12. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21(11):1539-1558.
13. Janssen Inc. Product Monograph, Risperdal 2013.
14. Jin H., Meyer J.M., Jeste D.V. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann. Clin. Psychiatry 2002, 14(1):59-64.
15. Kohen I., Gampel M., Reddy L., Manu P. Rapidly developing hyperglycemia during treatment with olanzapine. Ann. Pharmacother. 2008, 42(4):588-591.
16. Koller E.A., Doraiswamy P.M. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002, 22(7):841-852.
17. Koller E.A., Cross J.T., Doraiswamy P.M., Schneider B.S. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003, 23(6):735-744.
18. Koller E.A., Weber J., Doraiswamy P.M., Schneider B.S. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J. Clin. Psychiatry 2004, 65(6):857-863.
19. Kornegay C.J., Vasilakis-Scaramozza C., Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J. Clin. Psychiatry 2002, 63(9):758-762.
20. Koro C.E., Fedder D.O., L'Italien G.J., Weiss S.S., Magder L.S., Kreyenbuhl J., Revicki D.A., Buchanan R.W. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002, 325(7358):243.
21. Leslie D.L., Rosenheck R.A. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am. J. Psychiatry 2004, 161(9):1709-1711.
22. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry 2003, 160(2):290-296.
23. Lipscombe L.L., Levesque L., Gruneir A., Fischer H.D., Juurlink D.N., Gill S.S., Herrmann N., Hux J.E., Anderson G.M., Rochon P.A. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch. Intern. Med. 2009, 169(14):1282-1289.
24. Lipscombe L.L., Levesque L.E., Gruneir A., Fischer H.D., Juurlink D.N., Gill S.S., Herrmann N., Hux J.E., Anderson G.M., Rochon P.A. Antipsychotic drugs and the risk of hyperglycemia in older adults without diabetes: a population-based observational study. Am. J. Geriatr. Psychiatry 2011, 19(12):1026-1033.
25. Makhzoumi Z.H., McLean L.P., Lee J.H., Ibe A.I. Diabetic ketoacidosis associated with aripiprazole. Pharmacotherapy 2008, 28(9):1198-1202.
26. Marlowe K.F., Howard D., Chung A. New onset diabetes with ketoacidosis attributed to quetiapine. South. Med. J. 2007, 100(8):829-831.
27. Moride Y., Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J. Clin. Epidemiol. 1994, 47(7):731-737.
28. Muench J., Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature. J. Am. Board Fam. Pract. 2001, 14(4):278-282.
29. Ramaswamy K., Masand P.S., Nasrallah H.A. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann. Clin. Psychiatry 2006, 18(3):183-194.
30. Ramaswamy K., Kozma C.M., Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Saf. 2007, 30(7):589-599.
31. Roefaro J., Mukherjee S.M. Olanzapine-lnduced hyperglycemic nonketonic coma. Ann. Pharmacother. 2001, 35(3):300-302.
32. Schneeweiss S., Seeger J.D., Maclure M., Wang P.S., Avorn J., Glynn R.J. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am. J. Epidemiol. 2001, 154(9):854-864.
33. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry 2002, 159(4):561-566.
34. Smith M., Hopkins D., Peveler R.C., Holt R.I., Woodward M., Ismail K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 2008, 192(6):406-411.
35. Suissa S., Henry D., Caetano P., Dormuth C.R., Ernst P., Hemmelgarn B., Lelorier J., Levy A., Martens P.J., Paterson J.M., Platt R.W., Sketris I., Teare G., Canadian Network for Observational Drug Effects CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med. 2012, 6(4):e134-e140.
36. Takahashi M., Ohishi S., Katsumi C., Moriya T., Miyaoka H. Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report. Pharmacopsychiatry 2005, 38(4):183-184.
37. Wilson D.R., D'Souza L., Sarkar N., Newton M., Hammond C. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr. Res. 2003, 59(1):1-6.